Amyloid beta peptide immunotherapy in Alzheimer disease

• Published in: Revue neurologique Vol. 170; no. 12; pp. 739 - 748
• Main Authors: Delrieu, J., Ousset, P.J., Voisin, T., Vellas, B.
• Format: Journal Article
• Language: English
• Published: Paris Elsevier Masson SAS 01.12.2014; Masson
• Subjects: Adult and adolescent clinical studies; Alzheimer Disease - therapy; Alzheimer's disease; Amyloid beta-Peptides - immunology; Amyloid beta-Peptides - metabolism; Amyloid β peptide; Animals; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Humanized - therapeutic use; Anticorps monoclonaux; Biological and medical sciences; Biomarkers; Biomarqueurs; Clinical Trials as Topic - methods; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases; Drug Discovery - trends; Headache. Facial pains. Syncopes. Epilepsia. Intracranial hypertension. Brain oedema. Cerebral palsy; Humans; Immunotherapy; Immunotherapy - methods; Immunothérapie; Maladie d’Alzheimer; Medical sciences; Monoclonal antibodies; Nervous system (semeiology, syndromes); Neurology; Organic mental disorders. Neuropsychology; Peptide β amyloïde; Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Signal Transduction - drug effects; Signal Transduction - immunology; Vaccin; Vaccine; Amyloid β peptide; Maladie d’Alzheimer; Peptide β amyloïde; Immunotherapy; Vaccin; Monoclonal antibodies; Biomarkers; Vaccine; Biomarqueurs; Immunothérapie; Alzheimer's disease; Anticorps monoclonaux; Nervous system diseases; Treatment; Peptides; Alzheimer disease; Central nervous system disease; Degenerative disease; Amyloid; Monoclonal antibody; Cerebral disorder

Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process. Amyloid β peptide represents an important molecular target for intervention in Alzheimer's disease. The main purpose of this wor...